Among the identified inhibitors, Ansamitocin P-3 exhibits particularly pronounced inhibitory effects on ASGR1 protein in both liver cancer cell lines, with its efficacy increasing over extended treatment durations. The gene discussed is ASGR1; the disease is liver cancer.